AndrewSChiMD

Neurooncology

Director, Neuro-Oncology Program, Laura and Isaac Perlmutter Cancer Center Co-Director, Brain Tumor Center, NYU Langone Medical Center

Join to view full profile

Dr. Chi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Chi's full profile

Already have an account?

Office
240 E 38th St Fl 19
Laura and Isaac Perlmutter Cancer Center, NYU Langone Medical Center
New York, NY 10016
Phone+1 212-731-6267

Fax+1 646-754-9696
Is this information wrong?

Education & Training

Dana-Farber Cancer InstituteFellowship, Neuro-Oncology, 2006 - 2008
Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical SchoolChief Residency, Neurology, 2005 - 2006
Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical SchoolResidency, Neurology, 2003 - 2005
Massachusetts General HospitalInternship, Internal Medicine, 2002 - 2003
Chicago Medical School at Rosalind Franklin University of Medicine and ScienceClass of 2002

Certifications & Licensure

NY State Medical License 2015 - 2019
MA State Medical License 2006 - 2017

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012

Clinical Trials

A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Glioblastoma or Malignant Glioma Start of enrollment: 2015 Jun 01
Completed
Phase 1
Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers Start of enrollment: 2014 Mar 12
Completed
Phase 2
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma Start of enrollment: 2015 Nov 30
Terminated
Phase 2, Phase 3
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) Start of enrollment: 2015 Aug 17
Active, not recruiting
Phase 2
Avelumab With Hypofractionated Radiation Therapy in Adults With Isocitrate Dehydrogenase (IDH) Mutant Glioblastoma Start of enrollment: 2017 Mar 17
Completed
Phase 2
ONC201 in Adults With Recurrent H3 K27M-mutant Glioma Start of enrollment: 2017 Oct 31
Active, not recruiting
Phase 2
Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma Start of enrollment: 2018 Feb 07
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

Comprehensive mutational scanning of EGFR reveals TKI sensitivities of extracellular domain mutants.
Tikvah K Hayes, Elisa Aquilanti, Nicole S Persky, Xiaoping Yang, Erica E Kim, Lisa Brenan, Amy B Goodale, Douglas Alan, Ted Sharpe, Robert E Shue, Lindsay Westlake, Li...> ;Nature Communications. 2024 Mar 28
Longitudinal analysis of serum-derived extracellular vesicle RNA to monitor dacomitinib treatment response in EGFR-amplified recurrent glioblastoma patients.
Anudeep Yekula, Tiffaney Hsia, Robert R Kitchen, Sudipto K Chakrabortty, Wei Yu, Syeda M Batool, Brian Lewis, Antoni J Szeglowski, Ralph Weissleder, Hakho Lee, Andrew ...> ;Neuro-Oncology Advances. 2023 Sep 4
Neuro-Oncology Practice Clinical Debate: Early treatment or observation for patients with newly diagnosed oligodendroglioma and small-volume residual disease.
Shannon Fogh, Lauren Boreta, Jean L. Nakamura, Derek R. Johnson, Andrew S. Chi, Sylvia Kurz> ;Neuro-Oncology Practice. 2021 Feb 25
5 citations
Radiogenomics identifying important biological pathways in gliomas.
Rajan Jain, Andrew S. Chi> ;Neuro-Oncology. 2021 Feb 25
Erratum : Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo DNA synthesis, irrespective of molecular subt...
Jian Teng, Seyedali Hejazi, Lotte Hiddingh, Litia Carvalho, Mark C. de Gooijer, Hiroaki Wakimoto, Marco Barazas, Marie Tannous, Andrew S. Chi, David P. Noske, Pieter W...> ;Neuro-Oncology. 2020 Dec 1
63 citations
Dissecting the immunosuppressive tumor microenvironments in Glioblastoma-on-a-Chip for optimized PD-1 immunotherapy.
Xin Cui, Chao Ma, Varshini Vasudevaraja, Jonathan Serrano, Jie Tong, Yansong Peng, Michael Delorenzo, Guomiao Shen, Joshua D. Frenster, Renee Tyler Tan Morales, Weiyi ...> ;Elife. 2020 Sep 10
61 citations
“Real world” use of a highly reliable imaging sign: “T2-FLAIR mismatch” for identification of IDH mutant astrocytomas
Rajan Jain, Derek R. Johnson, Sohil H. Patel, Mauricio Castillo, Marion Smits, Martin J. van den Bent, Andrew S. Chi, Daniel P. Cahill> ;Neuro-Oncology. 2020 Jul 7
22 citations
Exploring Predictors of Response to Dacomitinib in EGFR -Amplified Recurrent Glioblastoma.
Andrew S. Chi, Daniel P. Cahill, David A. Reardon, Patrick Y. Wen, Tom Mikkelsen, David M. Peereboom, Eric T. Wong, Elizabeth R. Gerstner, Jorg Dietrich, Scott R. Plot...> ;JCO Precision Oncology. 2020 Jun 8
10 citations
Expression profiling of the adhesion G protein-coupled receptor GPR133 (ADGRD1) in glioma subtypes.
Joshua D. Frenster, Michael Kader, Scott Kamen, James Sun, Luis Chiriboga, Jonathan Serrano, Devin Bready, Danielle Golub, Niklas Ravn-Boess, Gabriele Stephan, Andrew ...> ;Neuro-Oncology Advances. 2020 Jan 1
23 citations
Functional and topographic effects on DNA methylation in IDH1/2 mutant cancers.
Ramona Bledea, Varshini Vasudevaraja, Seema Patel, James M. Stafford, Jonathan Serrano, Gianna Esposito, Lilian M. Tredwin, Nina Goodman, Andreas Kloetgen, John G. Gol...> ;Scientific Reports. 2019 Nov 14
107 citations
Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201.
Andrew S. Chi, Rohinton Tarapore, Matthew Hall, Nicole Shonka, Sharon Gardner, Yoshie Umemura, Ashley Sumrall, Ziad Khatib, Sabine Mueller, Cassie Kline, Wafik Zaky, S...> ;Journal of Neuro-Oncology. 2019 Oct 1
21 citations
PI3K/AKT/mTOR Pathway Alterations Promote Malignant Progression and Xenograft Formation in Oligodendroglial Tumors
Kensuke Tateishi, Taishi Nakamura, Tareq A. Juratli, Erik A. Williams, Yuko Matsushita, Shigeta Miyake, Mayuko Nishi, Julie J. Miller, Shilpa S. Tummala, Alexandria Fi...> ;Clinical Cancer Research. 2019 Jul 15
Publisher Correction: Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRI
K. Ina Ly, Bella Vakulenko-Lagun, Kyrre E. Emblem, Yangming Ou, Xiao Da, Rebecca A. Betensky, Jayashree Kalpathy-Cramer, Dan G. Duda, Rakesh K. Jain, Andrew S. Chi, Sc...> ;Scientific Reports. 2019 Jun 14
7 citations
MR imaging phenotype correlates with extent of genome-wide copy number abundance in IDH mutant gliomas.
Chih Chun Wu, Rajan Jain, Lucidio Neto, Seema Patel, Laila M. Poisson, Jonathan Serrano, Victor Ng, Sohil H. Patel, Dimitris G. Placantonakis, David Zagzag, John G. Go...> ;Neuroradiology. 2019 May 27
26 citations
PIK3CA activating mutations are associated with more disseminated disease at presentation and earlier recurrence in glioblastoma
Shota Tanaka, Tracy T. Batchelor, A. John Iafrate, Dora Dias-Santagata, Darrell R. Borger, Leif W. Ellisen, Daniel Yang, David N. Louis, Daniel P. Cahill, Andrew S. Chi> ;Acta Neuropathologica Communications. 2019 Apr 29
47 citations
First clinical experience with DRD2/3 antagonist ONC201 in H3 K27M-mutant pediatric diffuse intrinsic pontine glioma: a case report.
Matthew Hall, Yazmin Odia, Joshua E. Allen, Rohinton Tarapore, Ziad Khatib, Toba N. Niazi, Doured Daghistani, Lee Schalop, Andrew S. Chi, Wolfgang Oster, Minesh P. Mehta> ;Journal of Neurosurgery. Pediatrics. 2019 Apr 5
45 citations
Cell Surface Notch Ligand DLL3 is a Therapeutic Target in Isocitrate Dehydrogenase-mutant Glioma
Marissa Spino, Sylvia Kurz, Luis Chiriboga, Jonathan Serrano, Briana Zeck, Namita Sen, Seema Patel, Guomiao Shen, Varshini Vasudevaraja, Aristotelis Tsirigos, Carter M...> ;Clinical Cancer Research. 2019 Feb 15
90 citations
Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial.
Patrick Y. Wen, Mehdi Touat, Brian M. Alexander, Ingo K. Mellinghoff, Shakti Ramkissoon, Christine McCluskey, Kristine Pelton, Sam Haidar, Sankha S. Basu, Sarah C. Gaf...> ;Journal of Clinical Oncology. 2019 Feb 4
44 citations
There is an exception to every rule-T2-FLAIR mismatch sign in gliomas.
Derek R. Johnson, Timothy J. Kaufmann, Sohil H. Patel, Andrew S. Chi, Matija Snuderl, Rajan Jain> ;Neuroradiology. 2019 Feb 1
9 citations
Genetically distinct glioma stem-like cell xenografts established from paired glioblastoma samples harvested before and after molecularly targeted therapy.
Shota Tanaka, Samantha Luk, Juri Kiyokawa, Maristela L. Onozato, A. John Iafrate, Khalid Shah, Robert L. Martuza, Samuel D. Rabkin, Tracy T. Batchelor, Daniel P. Cahil...> ;Scientific Reports. 2019 Jan 15
12 citations
Phase II Study of Iniparib with Concurrent Chemoradiation in Patients with Newly Diagnosed Glioblastoma
Jaishri O. Blakeley, Stuart A. Grossman, Andrew S. Chi, Tom Mikkelsen, Myrna R. Rosenfeld, Manmeet Ahluwalia, L. Burt Nabors, April F. Eichler, Ignacio Garcia Ribas, S...> ;Clinical Cancer Research. 2019 Jan 1
9 citations
Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRI.
K. Ina Ly, Bella Vakulenko-Lagun, Kyrre E. Emblem, Yangming Ou, Xiao Da, Rebecca A. Betensky, Jayashree Kalpathy-Cramer, Dan G. Duda, Rakesh K. Jain, Andrew S. Chi, Sc...> ;Scientific Reports. 2018 Nov 20
39 citations
Predicting Genotype and Survival in Glioma Using Standard Clinical MR Imaging Apparent Diffusion Coefficient Images: A Pilot Study from The Cancer Genome Atlas
Chih Chun Wu, Rajan Jain, Alireza Radmanesh, Laila M. Poisson, Wan-Yuo Guo, David Zagzag, Matija Snuderl, Dimitris G. Placantonakis, John G. Golfinos, Andrew S. Chi> ;AJNR. American Journal of Neuroradiology. 2018 Oct 1
20 citations
Quantitative sodium imaging and gliomas: a feasibility study
Lucidio Neto, Guillaume Madelin, Terlika Pandit Sood, Chih-Chun Wu, Douglas Kondziolka, Dimitris G. Placantonakis, John G. Golfinos, Andrew S. Chi, Rajan Jain> ;Neuroradiology. 2018 Jun 3
89 citations
Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate
Ovidiu C. Andronesi, Isabel Arrillaga-Romany, K. Ina Ly, Wolfgang Bogner, Eva M. Ratai, Kara Reitz, A. John Iafrate, Jorg Dietrich, Elizabeth R. Gerstner, Andrew S. Ch...> ;Nature Communications. 2018 Apr 16
Join now to see all

Journal Articles

Predicting Genotype and Survival in Glioma Using Standard Clinical MR Imaging Apparent Diffusion Coefficient Images: A Pilot Study from the Cancer Genome Atlas
D Zagzag, M Snuderl, A S Chi, American Journal of Neuroradiology

Lectures

Integrated clinical experience with ONC201 in H3 K27M glioma.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Evolving Biomarkers for Outcome: Strengths and Pitfalls
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018